Randomized comparison of etoposide pharmacokinetics after oral etoposide phosphate and oral etoposide
1997

Comparing Etoposide Phosphate and Etoposide in Cancer Treatment

Sample size: 17 publication Evidence: moderate

Author Information

Author(s): RS de Jong, NH Mulder, DRA Uges, S Kau, B Winograd, DTh Sleijfer, HJM Groen, PHB Willemsel, WTA van der Graaf, EGE de Vries

Primary Institution: University Hospital Groningen

Hypothesis

Does etoposide phosphate provide better pharmacokinetics than oral etoposide?

Conclusion

Oral etoposide phosphate does not offer a clinically relevant benefit over oral etoposide.

Supporting Evidence

  • The median AUCinf of etoposide was 77.7 mg 1-1 h after etoposide phosphate.
  • Etoposide phosphate was undetectable in plasma after oral administration.
  • Patients received a total of 59 treatment courses.
  • Grade III or IV leucopenia developed in three patients (18%).
  • Pharmacokinetic variability was high for both drugs.

Takeaway

This study looked at two types of cancer medicine, and found that one didn't work any better than the other.

Methodology

Patients were randomized to receive either etoposide phosphate or etoposide, with pharmacokinetic sampling conducted.

Limitations

The study had a small sample size and did not directly compare toxicities of both drugs.

Participant Demographics

Patients aged 18-75 with solid tumors, 12 males and 5 females.

Statistical Information

P-Value

0.05

Confidence Interval

95% Cl 61.3-100.5

Statistical Significance

p=0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication